AI Enhancing Preclinical Safety and Reducing Burden
Deciphex’s AI-powered platforms are revolutionizing preclinical safety assessments, ensuring that unsafe drugs and compounds are identified before reaching human clinical trials. By automating and optimizing safety evaluations, AI helps deliver more consistent preclinical results, reducing the time and resources required for these studies. This ensures that potential safety risks are identified earlier, improving the overall reliability of preclinical research.
Preventing Unsafe Compounds from Entering Clinical Trials
AI improves early safety assessments by catching potential issues earlier in the research process. This helps ensure that unsafe drugs are identified before advancing to human trials, reducing risks for patients and improving the likelihood of successful drug development. By filtering toxic compounds faster and more reliably, AI-powered safety evaluations ensure a more efficient path to market.
Improving Preclinical Research Outcomes
Approximately 1 in every 5,000 - 10,000 candidate compounds identified in early discovery phases progresses to human clinical trials, with some therapeutic areas (such as cancer treatment) seeing even lower success rates due to complex biology. Effective screening and characterization of new candidates is critical to ensure those selected to progress are both economically viable, and provide a meaningful impact on patient outcomes. Through our extensive collaboration with Charles River Laboratories we have developed Foresight, a suite of pre-trained AI models that facilitate faster qualification of new candidates during critical Lead Optimization and Dose Range Finding development stages. Providing deeper insights into the performance of new candidates and reducing pathologist review time by over 20%, Foresight facilitates earlier determination of potentially unsafe compounds, minimizing the likelihood of advancing unsuitable candidates, thereby saving resources & reducing risks to patients.
Reducing Animal Burden in Preclinical Studies
A significant aspect of AI’s impact is its ability to reduce the reliance on animal testing in preclinical trials. Through initiatives like the IHI JU VICT3R project, which introduces virtual controls, Deciphex is helping reduce the need for live animal testing. This not only aligns with ethical goals but also allows for more cost-effective and efficient safety evaluations without compromising scientific accuracy.
Faster, More Reliable Preclinical Safety Evaluations
With AI automating large portions of the preclinical safety evaluation process, studies are completed, and achieving consistent results with fewer unnecessary repetitions while reducing the testing burden. The use of virtual controls in the VICT3R initiative, alongside Deciphex’s broader AI tools, helps streamline workflows, providing faster, more reliable safety evaluations that ensure only safe compounds progress to clinical trials. This results in quicker, more confident decision-making throughout the drug development process, ultimately ensuring safer outcomes for patients.
Resources
